Esperion Reports Top-Line Results From Pivotal Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint, Achieveded Added 20% On-Treatment LDL-C Lowering On Background Maximally Tolerated Statin Therapy